Zimmer Biomet (ZBH) reported Q2 2026 net sales of $2.177B, up 4.8% on a reported basis and 4.0% in organic constant currency. Growth across hips, specialty businesses, and technology offset weakness in certain other product lines, supporting a modestly positive earnings backdrop.
Zimmer Biomet (ZBH) reported Q2 2026 net sales of $2.177B, up 4.8% on a reported basis and 4.0% in organic constant currency. Growth across hips, specialty businesses, and technology offset weakness in certain other product lines, supporting a modestly positive earnings backdrop.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
